Thymopentin: stability considerations and potency by various routes of administration
- 1 March 1985
- journal article
- research article
- Published by Springer Nature in Survey of Immunologic Research
- Vol. 4 (S1) , 17-23
- https://doi.org/10.1007/bf02919052
Abstract
Summary Thymopentin, the synthetic pentapeptide Arg-Lys-Asp-Val-Tyr corresponding to amino acids 32-36 of thymopoietin, was rapidly degraded in human plasma (T.1/2 = 30 s) and this was shown to be due to proteolytic enzymes in plasma. The biological potency of thymopentin varied greatly with the route of administration, a finding possibly related to its short half-life. Intravenous infusion provided the most potent and bolus intraperitoneal injection the least potent mode of administration. Thus the route and rate of administration are critical factors in determining the effective dose being received by the animal.Keywords
This publication has 26 references indexed in Scilit:
- Thymopentin (TP-5) potency in vivo is enhanced by slow infusionInternational Journal of Peptide and Protein Research, 2009
- CONTRASTING EFFECTS OF THYMOPENTIN AND SPLENOPENTIN ON THE CAPACITY OF FEMALE MICE TO REJECT SYNGENEIC MALE SKINTransplantation, 1984
- Comparative efficacy of various routes of administration of thymopentin (TP‐5) with consideration of degradative mechanismsInternational Journal of Peptide and Protein Research, 1983
- Thymopoietin pentapeptide (TP-5) improves clinical parameters and lymphocyte subpopulations in atopic dermatitisJournal of the American Academy of Dermatology, 1983
- Clinical response to therapy with thymopoietin pentapeptide (TP-5) in rheumatoid arthritisAnnals of the Rheumatic Diseases, 1982
- Complete amino acid sequences of bovine thymopoietins I, II, and III: closely homologous polypeptidesBiochemistry, 1981
- SHORT IN VITRO HALF‐LIFE OF THYMOPOIETIN 32–36 PENTAPEPTIDE IN HUMAN PLASMAInternational Journal of Peptide and Protein Research, 1979
- Contraception and inhibition of ovulation by minipump infusion of the luteinizing hormone releasing hormone, active analogs and antagonistsBiochemical and Biophysical Research Communications, 1976
- Electrophysiological changes similar to those of myasthenia gravis in rats with experimental autoimmune thymitis.Journal of Neurology, Neurosurgery & Psychiatry, 1968
- EXPERIMENTAL AUTOIMMUNE THYMITIS AN ANIMAL MODEL OF HUMAN MYASTHENIA GRAVISThe Lancet, 1966